Pulmonary hypertension, endothelial dysfunction, and their correction with lisinopril in patients with heart failure in combination of ischemic heart disease and chronic obstructive pulmonary disease

Kardiologiya

Volumn 46, Issue 9, 2006, Pages 36-40

  Pribylov, S A ^a  

^a KURSK STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Endothelial dysfunction; Heart failure; Lisinopril; Pulmonary hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DRUG ADMINISTRATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; LISINOPRIL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33750209718     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of the endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
2. Pietra G.G., Capron F., Stewart S. et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43:12: Suppl S:25S-32S.
3. Yanagisawa M., Masaki T. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol 1989;38:12:1877-1883.
4. Gibbons G.H. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997;79:3-8.
5. Vanhoutte P.M., Mombouli J.V. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996;39:229-238.
6. Yanagisawa M., Kurihara H., Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998;332:411-415.
7. Cowburn P.J., Cleland J.G.F. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J 2001;22:19:1772-1784.
8. Peacock A., Naeije R., Galie N., Reeves J.T. End points in pulmonary arterial hypertension: the way forward. Eur Resp J 2004;23:6:947-953.
9. Barst R.J., Langleben D., Frost A. et al. Sitaxsentan Therapy for Pulmonary Arterial Hypertension. Am J Resp Crit Care Med 2004;169:441-447.
10. Celermajer D.S. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
11. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998;105:32-39.
12. Taddei S., Virais A., Ghiadom L. et al. Effects of antihypertensive drugs on endothelial dysfunction clinical implications. Drugs 2002;62:265-284.
13. Rajagopalan S., Harrison D. Reversing endothelial dysfunction with ACE inhibitors: A new TREND? Circulation 1996;94:240-243.
14. Dinh-Xuan A.T., Higenbottam T.W., Clelland C. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-1547.
15. Carville C.X., Raffestin B., Eddahibi A. et al. Loss of endothelium-dependent relaxation in proximal pulmonary arteries from rats exposed to chronic hypoxia: effects of in vivo and in vitro supplementation with L-arginine. J Cardiovasc Pharmacol 1993;22:889-896.
16. Park S.H., Shub C., Nobrega T.P. et al. Two dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr 1996;9:119-128.
17. Thuillez C., Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Human Hypertens 2005;19:S21-S25.
18. Monge J.C. Neurohormonal markers of clinical outcome in cardiovascular disease: is endothelin the best one? J Cardiovasc Pharmacol 1998;32:Suppl 2:S36-S42.
19. Haug C., Koenig W., Hoeher M. et al. Direct enzyme immunometric measurement of plasma big endothelin-I concentrations and correlation with indicators of left ventricular function. Clin Chem 1998;44:2:239-243.
20. Cacoub P., Dorent R., Nataf P. et al. Endothelin-I in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997;33:1:196-200.
21. Humbert M., Sitbon O., Simonneau G. Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2004;351:1425-1436.